# A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients

> **NCT06063590** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cellcolabs Clinical SPV Limited** · enrollment: 12 (actual)

## Conditions studied

- Aging Frailty

## Interventions

- **BIOLOGICAL:** StromaForte

## Key facts

- **NCT ID:** NCT06063590
- **Lead sponsor:** Cellcolabs Clinical SPV Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-22
- **Primary completion:** 2025-08-28
- **Final completion:** 2025-08-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06063590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06063590, "A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06063590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*